FITO-AFRODISIACO / ANTIPARKINSON: Extrato de Macuna
Macuna Extract: Mucuna extract, commonly known as velvet bean, has been used by Ayurvedic practitioners for centuries in the management of Parkinson's disease and nervous debility. It has also been used in formulations to control depression and improve mental alertness. Among other natural phytochemicals, Mucuna also contains L-Dopa (l-dihydroxyphenylalanine). It may be the L-Dopa content that provides much of Mucuna's benefits. These benefits include the reduction of cholesterol and blood sugar levels in experimental models. Mucuna has been prescribed as an aphrodisiac by Ayurvedic practitioners as well. A recent study revealed that the herb is useful in improving sexual performance in normal male animal models. The authors of this study concluded that the effects on mating behavior and sexual performance in the male rats could partially be attributed to the androgenic effect of Mucuna.
VEJA MAIS EM Horny Goat Weed
Este Blog, criado em set/2001, é dedicado às Pessoas com Parkinson (PcP's), seus familiares, bem como aos profissionais da saúde que vivenciam a situação de stress que acompanha a doença. A idéia é oferecer aos participantes um meio de atualizar e de trocar informações sobre a doença de Parkinson e encorajar as PcP's a expressar sentimentos no pressuposto de que o grupo infunde esperança, altruísmo e o aumento da auto-estima. E um alerta: Parkinson não é exclusividade de idosos!
domingo, 1 de dezembro de 2002
Agonista e Antidepressivo ao mesmo tempo ...
Agonista e Antidepressivo ao mesmo tempo ...
Antidepressant effects of pramipexole (Sifrol / Mirapex), a novel dopamine receptor agonist by
Maj J; Rog�z Z; Skuza G; Koodziejczyk K
Institute of Pharmacology,
Polish Academy of Sciences, Krak�ow
J Neural Transm, 1997, 104:4-5, 525-33
ABSTRACT
Pramipexole (2-amino-4,5,6,7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochl oride), a new dopamine receptor agonist with preference for D3 compared to D2 and D4 receptors, was tested in rats in respect of its potential antidepressant activity. In the forced swimming test the drug under study, given three times in rats, reduced the immobility time. In the forced swimming test, joint treatment with antidepressants (imipramine, amitriptyline) and pramipexole evoked a more potent effect than any of the drugs given alone; however, the locomotor hyperactivity was weaker after joint administration. Citalopram and fluoxetine, inactive per se in the forced swimming tests, visibly enhanced the antidepressant-like effect of pramipexole but, on the other hand, they attenuated the locomotor hyperactivity evoked by the drug. Repeated treatment with pramipexole (0.3 or 1 mg/kg, twice daily for 14 days) increased the locomotor activity measured at 1 h after the last dose. Repeated administration of pramipexole (as above) potentiated the D-amphetamine- or quinpirole-induced locomotor hyperactivity. The obtained results indicate that, in the tests used, pramipexole evokes effects similar to those of typical antidepressants and, at the same time, enhances their activity (the forced swimming test in rats); therefore it may be regarded as a potential antidepressant drug.
Veja mais em Mirapex
Antidepressant effects of pramipexole (Sifrol / Mirapex), a novel dopamine receptor agonist by
Maj J; Rog�z Z; Skuza G; Koodziejczyk K
Institute of Pharmacology,
Polish Academy of Sciences, Krak�ow
J Neural Transm, 1997, 104:4-5, 525-33
ABSTRACT
Pramipexole (2-amino-4,5,6,7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochl oride), a new dopamine receptor agonist with preference for D3 compared to D2 and D4 receptors, was tested in rats in respect of its potential antidepressant activity. In the forced swimming test the drug under study, given three times in rats, reduced the immobility time. In the forced swimming test, joint treatment with antidepressants (imipramine, amitriptyline) and pramipexole evoked a more potent effect than any of the drugs given alone; however, the locomotor hyperactivity was weaker after joint administration. Citalopram and fluoxetine, inactive per se in the forced swimming tests, visibly enhanced the antidepressant-like effect of pramipexole but, on the other hand, they attenuated the locomotor hyperactivity evoked by the drug. Repeated treatment with pramipexole (0.3 or 1 mg/kg, twice daily for 14 days) increased the locomotor activity measured at 1 h after the last dose. Repeated administration of pramipexole (as above) potentiated the D-amphetamine- or quinpirole-induced locomotor hyperactivity. The obtained results indicate that, in the tests used, pramipexole evokes effects similar to those of typical antidepressants and, at the same time, enhances their activity (the forced swimming test in rats); therefore it may be regarded as a potential antidepressant drug.
Veja mais em Mirapex
Assinar:
Postagens (Atom)